CN104769430B - 流感中的风险分层 - Google Patents

流感中的风险分层 Download PDF

Info

Publication number
CN104769430B
CN104769430B CN201380046905.6A CN201380046905A CN104769430B CN 104769430 B CN104769430 B CN 104769430B CN 201380046905 A CN201380046905 A CN 201380046905A CN 104769430 B CN104769430 B CN 104769430B
Authority
CN
China
Prior art keywords
ifi27
seq
gene product
patient
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380046905.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104769430A (zh
Inventor
安东尼·麦克林
本杰明·唐
格兰特·彼得·帕内尔
马里亚姆·苏查尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Local Medical Treatment Area In Ni Ping Lanshan County
Original Assignee
Local Medical Treatment Area In Ni Ping Lanshan County
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902954A external-priority patent/AU2012902954A0/en
Application filed by Local Medical Treatment Area In Ni Ping Lanshan County filed Critical Local Medical Treatment Area In Ni Ping Lanshan County
Publication of CN104769430A publication Critical patent/CN104769430A/zh
Application granted granted Critical
Publication of CN104769430B publication Critical patent/CN104769430B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201380046905.6A 2012-07-10 2013-07-10 流感中的风险分层 Active CN104769430B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902954A AU2012902954A0 (en) 2012-07-10 Risk stratification in influenza
AU2012902954 2012-07-10
PCT/AU2013/000765 WO2014008545A1 (en) 2012-07-10 2013-07-10 Risk stratification in influenza

Publications (2)

Publication Number Publication Date
CN104769430A CN104769430A (zh) 2015-07-08
CN104769430B true CN104769430B (zh) 2018-12-14

Family

ID=49915252

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380046905.6A Active CN104769430B (zh) 2012-07-10 2013-07-10 流感中的风险分层

Country Status (10)

Country Link
US (2) US10036075B2 (https=)
EP (1) EP2872891B1 (https=)
JP (1) JP6097388B2 (https=)
KR (1) KR20150040289A (https=)
CN (1) CN104769430B (https=)
AU (1) AU2013289854B2 (https=)
BR (1) BR112015000685A2 (https=)
CA (1) CA2877400A1 (https=)
DK (1) DK2872891T3 (https=)
WO (1) WO2014008545A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3367099B1 (en) 2012-02-09 2021-05-26 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2015103664A1 (en) * 2014-01-09 2015-07-16 Nepean Blue Montains Local Health District Risk stratification in influenza
BR112017002884A2 (pt) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
CN111624345A (zh) 2014-12-11 2020-09-04 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
EP3146974A1 (en) 2015-09-25 2017-03-29 Universite Claude Bernard - Lyon 1 Biomarkers for early determination of severity of influenza related disease
EP3423590A4 (en) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. DETERMINANTS OF RNA TO DIFFERENTIATE BACTERIAL VIRAL INFECTIONS
IL287757B (en) 2016-03-03 2022-07-01 Memed Diagnostics Ltd Analyzing rna for diagnosing infection type
EP3482201B1 (en) 2016-07-10 2022-12-14 Memed Diagnostics Ltd. Early diagnosis of infections
EP3482200B1 (en) 2016-07-10 2022-05-04 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
US12344893B2 (en) 2018-06-05 2025-07-01 Washington University Nasal genes used to identify, characterize, and diagnose viral respiratory infections
JP7846017B2 (ja) * 2020-04-09 2026-04-14 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 気道感染症の診断のためのバイオマーカー

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541976A (zh) * 2006-08-11 2009-09-23 贝勒研究院 利用血液白细胞中的基因表达标记物的急性感染的鉴别诊断

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792626A (en) * 1996-09-18 1998-08-11 Incyte Pharmaceuticals, Inc. Human interferon-inducible protein
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US7214498B2 (en) * 2001-03-23 2007-05-08 Benaroya Research Institute At Virginia Mason Tumor associated antigens and methods of using the same
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
WO2005068664A2 (en) * 2004-01-09 2005-07-28 The Regents Of The University Of California Cell-type-specific patterns of gene expression
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
WO2007034280A2 (en) * 2005-09-19 2007-03-29 Moshe Amihood Blay Composition and method for prevention of influenza
WO2009148150A1 (ja) * 2008-06-06 2009-12-10 国立大学法人富山大学 インフルエンザウィルス検出用デバイス
WO2010076788A2 (en) * 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2011008349A2 (en) * 2009-05-26 2011-01-20 Duke University Methods of identifying infectious disease and assays for identifying infectious disease
EP2451476A4 (en) 2009-07-06 2013-07-03 Alnylam Pharmaceuticals Inc BIOTRAITEMENT BASED ON CELLS
US20120214705A1 (en) * 2009-09-28 2012-08-23 The Regents Of The University Of California Office of Technology, Beta-defensin 2 genetic variation predicts h. pylori susceptibility
EP2751286A1 (en) * 2011-09-04 2014-07-09 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Prognostic methods and compositions for predicting interferon treatment eficacy in a subject

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541976A (zh) * 2006-08-11 2009-09-23 贝勒研究院 利用血液白细胞中的基因表达标记物的急性感染的鉴别诊断

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Temporal Dynamics of Host Molecular Responses Differentiate Symptomatic and Asymptomatic Influenza A Infection;Yongsheng Huang et al.;《PLoS Genetics》;20110831;第7卷(第8期);e1002234 *

Also Published As

Publication number Publication date
KR20150040289A (ko) 2015-04-14
EP2872891A1 (en) 2015-05-20
CA2877400A1 (en) 2014-01-16
US20150322538A1 (en) 2015-11-12
WO2014008545A1 (en) 2014-01-16
CN104769430A (zh) 2015-07-08
EP2872891A4 (en) 2016-01-20
JP6097388B2 (ja) 2017-03-15
BR112015000685A2 (pt) 2017-11-28
AU2013289854B2 (en) 2016-03-24
US10036075B2 (en) 2018-07-31
JP2015530868A (ja) 2015-10-29
AU2013289854A2 (en) 2015-02-26
DK2872891T3 (da) 2019-05-13
AU2013289854A1 (en) 2015-01-22
EP2872891B1 (en) 2019-03-13
US20180298455A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
CN104769430B (zh) 流感中的风险分层
Guo et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19
Traister et al. Phenotypic and genotypic association of epithelial IL1RL1 to human TH2-like asthma
US9164094B2 (en) Biomarkers to identify HIV-specific T-cell subsets
Guan et al. Inverse correlation of expression of microRNA‐140‐5p with progression of multiple sclerosis and differentiation of encephalitogenic T helper type 1 cells
JP2016526888A (ja) 敗血症バイオマーカー及びそれらの使用
Xu et al. Nuclear carbonic anhydrase 6B associates with PRMT5 to epigenetically promote IL-12 expression in innate response
US20250188542A1 (en) Enrichment and characterization of rare circulating cells, including progenitor cells, from peripheral blood, and uses thereof
Yang et al. Diagnostic value of miR‐103 in patients with sepsis and noninfectious SIRS and its regulatory role in LPS‐induced inflammatory response by targeting TLR4
Ghazanfari et al. Is mannose‐binding lectin serum concentration a reliable predictor for recurrent vulvovaginal candidiasis?
Malato et al. The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in myalgic encephalomyelitis/chronic fatigue syndrome: A meta-analysis of public DNA methylation and gene expression data
Bérubé et al. Future clinical implications emerging from recent genome-wide expression studies in asthma
Gunter-Rahman et al. Hypoxia in extravillous trophoblasts links maternal obesity and offspring neurobehavior
He et al. Identification and validation of the inflammatory response-related LncRNAs as diagnostic biomarkers for acute ischemic stroke
Li et al. Identification of pyroptosis‑related genes in neuropathic pain based on bioinformatics analysis
Singh et al. Transcriptome Analysis of Dermal Fibroblasts Derived From Visceral Leishmaniasis and Post–Kala-Azar Dermal Leishmaniasis Patients Reveal Disease-Specific Gene Expression and Pathological Regulation
Sun et al. Classification of CHD7 rare variants in Chinese congenital hypogonadotropic hypogonadism patients and analysis of their clinical characteristics
WO2015103664A1 (en) Risk stratification in influenza
CN115103918A (zh) 自闭症谱系障碍的检测和治疗
EP3908668A1 (en) Compositions and methods for predicting lung function decline in idiopathic pulmonary fibrosis
KR102202120B1 (ko) 알츠하이머 질환의 진단 또는 치료를 위한 Ｕｂｅ２ｈ의 용도
Bingen Monocyte Macrophage Biomarkers of Multiple Sclerosis in an Underrepresented Minority Population
KR20200074545A (ko) Cd8+ 메모리 t 세포 매개성 질환의 예방 또는 치료용 약학 조성물
AlChalabi et al. Role of SAgs Produced by Staphylococcus aureus, rs893629 in TLR2 Gene in Progression of Recurrent Tonsillitis
Szymańska-Czerwińska et al. Prevalence, risk factors and genetic diversity of Chlamydia felis in cats

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant